Joshua Lee
Addiction Medicine · New York, NYNPI 1114132701
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 26.8% of the total. 2025 is the largest year on record at $386, 2.6 times the $149 reported in 2019.
Across 70 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$398
- Boehringer Ingelheim$270
- GSK$150
- Alphatec Spine, Inc$144
- AstraZeneca$125
- Medline Industries LP$110
- plus $288 from 7 others
Across 120 payments — averaging $9412.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$941K
- Indivior Inc.$189K
What the payments were for
- Food & beverage$1,486100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 23 | $398 |
| Boehringer Ingelheim | 17 | $270 |
| GSK | 8 | $150 |
| Alphatec Spine, Inc | 1 | $144 |
| AstraZeneca | 1 | $125 |
| Medline Industries LP | 2 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $110 |
| Johnson & Johnson(2 entities) | 5 | $70 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Invivyd Inc | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$125
How this compares
$1,486 in reported general payments places this provider in the 75th percentile of 125 addiction medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $9,342 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 23 | $4,297 |
| Buprenorphine Hcl | 21 | $233 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in New York
- John MarianiNew York$38K
- Stefan KantrowitzNew York$33K
- Ramon RaveloNew York$13K
- Stuart GitlowNew York$7K
- James WolbergNew York$5K
- Lloyd ZimmermanNew York$1K
- Stephanie SeaslyNew York$829
- James McKnightNew York$694
- Elias DakwarNew York$514
- Alina BabarNew York$334
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.